Pharmacokinetics of Bictegravir in Older Japanese People Living with HIV-1-Reference-Cited by-同舟云学术

Pharmacokinetics of Bictegravir in Older Japanese People Living with HIV-1

Published:2023-04-13 Issue:2 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Kawashima Akira¹,Trung Hieu Tran¹²,Watanabe Koji¹^ORCID,Takano Misao¹,Deguchi Yoshimi¹,Kinoshita Mai¹,Uemura Haruka¹,Yanagawa Yasuaki¹,Gatanaga Hiroyuki¹²,Kikuchi Yoshimi¹,Oka Shinichi¹²,Tsuchiya Kiyoto¹

Affiliation:

1. AIDS Clinical Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan

2. The Joint Research Center for Human Retrovirus Infection Kumamoto University Campus, Kumamoto City, Kumamoto, Japan

Abstract

BIC is a potent integrase strand transfer inhibitor (INSTI), widely used for the treatment of HIV-1 as part of a once-daily single-tablet regimen that includes emtricitabine and tenofovir alafenamide (BIC+FTC+TAF). Although the safety and efficacy of BIC+FTC+TAF have been confirmed in older patients with HIV-1, PK data in this patient population remain limited.

Funder

Gilead Sciences

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.05079-22

Reference16 articles.

1. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents—A Working Group of the Office of AIDS Research Advisory Council (OARAC). 2022. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf. Retrieved 21 September 2022.

2. Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV : Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

3. Zhang H, Custodio JM, Wei X, Wang H, Vu A, Ling J, Martin H, Quirk E, Kearney BP. 2017. Clinical pharmacology of the HIV intregrase strand transfer inhibitor bictegravir. In Conference on Retroviruses and Opportunistic Infections. CROI Foundation, Seattle, WA.

4. Gilead. 2018. Biktarvy. Highlights of prescribing information. https://www.gilead.com/-/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf. Accessed 16 December 2019.

5. Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of a High-Performance Liquid Chromatography Coupled With Ultraviolet Detection Method for Quantification of Bictegravir in Human Plasma;Therapeutic Drug Monitoring;2024-06-21

2. Treatment outcomes amongst older people with HIV infection receiving antiretroviral therapy;AIDS;2024-01-12

3. Steady-state pharmacokinetics of plasma tenofovir alafenamide (TAF), tenofovir (TFV) and emtricitabine (FTC), and intracellular TFV-diphosphate and FTC-triphosphate in HIV-1 infected old Japanese patients treated with bictegravir/FTC/TAF;Global Health & Medicine;2023-08-31